A case of polymyositis and vasculitis induced by ovulation induction therapy with gonadotropin-releasing hormone

Case report OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-29 ⓘ

A 53-year-old woman developed severe polymyositis and vasculitis five days after receiving gonadotropin-releasing hormone for ovulation induction, with symptoms improving following treatment with corticosteroids, aspirin, and pentoxyphyllin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gonadotropin-releasing hormone (GnRH) is the first key hormone of reproduction. GnRH analogs are extensively used in in vitro fertilization and treatment of sex hormone-dependent cancers due to their ability to bring about 'chemical castration'. Recently it has been showed that it also plays an important role in the modulation of the immune system. We report a case of vasculitis and histologically proven severe polymyositis developed 5 days after GnRH administration due to ovulation induction in an infertile patient with no previous history of autoimmune diseases. After treatment with corticosteroids (prednisone, 30 mg daily), aspirin, and pentoxyphyllin in combination with rehabilitation, an amelioration of muscle impairment was observed.

My notes (saved in your browser only)

MeSH descriptors

Gonadotropin-Releasing Hormone Ovulation Induction Polymyositis Vasculitis Adrenal Cortex Hormones Adrenal Cortex Hormones Adult Biopsy Female Gonadotropin-Releasing Hormone Humans Immune System Infertility, Female Infertility, Female Infertility, Female Muscles Muscles Muscles Ovulation Induction Polymyositis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (18)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:07:31.877465+00:00
unpaywall
last seen: 2026-11-09T06:31:04.326590+00:00
License: CC0 · commercial use OK